Answer
The most frequently reported adverse reactions to canakinumab were infections, predominantly of the upper respiratory tract.
Sources for this answer
- Ilaris 150mg/ml Solution for InjectionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 8Document updated
Sources checked